---
document_datetime: 2025-10-22 16:07:35
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bekemv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bekemv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 14.4467933
conversion_datetime: 2025-12-26 09:13:25.428018
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BEKEMV

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 02/05/2025                          |                                             | SmPC and PL                      | To update sections 4.4, 4.8, 5.1 and 5.2 of the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000263414   | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.4, 4.8, 5.1 and 5.2 of the SmPC and section 3 and 4 of the Package Leaflet following assessment of the same change for the reference product, in order to update efficacy and pharmacokinetic information based on final results from study ECU-MG-303; this is a Phase 3, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in pediatric patients with refractory generalized myasthenia gravis (gMG). - In addition, the applicant took the opportunity to update Section 4.2 of the SmPC, where the clinical data referred to in this paragraph relates to PNH Soliris clinical trials, not the Bekemv biosimilar data. The MAH replaced BEKEMV with eculizumab. - Furthermore, the MAH took the opportunity to introduce information regarding polysorbate in line with the QRD template. - Also, the MAH took the opportunity to remove the local representative for the   | SmPC and section 3 and 4 of the Package Leaflet following assessment of the same change for the reference product, in order to update efficacy and pharmacokinetic information based on final results from study ECU-MG-303; this is a Phase 3, open- label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in pediatric patients with refractory generalized myasthenia gravis (gMG). In addition, the applicant took the opportunity to update Section 4.2 of the SmPC, where the clinical data referred to in this paragraph relates to PNH Soliris clinical trials, not the Bekemv biosimilar data. The MAH replaced BEKEMV with eculizumab.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | made editorial changes to the contact information for the local representatives for Iceland, Lithuania and Portugal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000264089 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                            | 02/05/2025 | N/A |                                                                                                                                                                                                                                                                                                   |
| Variation type II / EMA/VR/0000247434 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted | 25/04/2025 |     | B.II.b.1.a Secondary packaging site. B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes |

<div style=\"page-break-after: always\"></div>